Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Completed · Not applicable

Conditions studied: Atrial Fibrillation, Heart Failure

In brief

The purpose of this study is to characterize the feasibility and impact of a diagnostic tool that may help clinicians identify when patients are at higher risk of visiting the hospital for a heart failure event. The study will use a non-experimental device that is inserted just under the skin of the chest, which continuously monitors the heart rhythm in combination with an experimental web-based heart failure risk status. Patients with atrial fibrillation and heart failure will be evaluated to collect data about the potential of this risk status to help improve patient outcome.

Key facts

Study ID

NCT01486316

Run by

Medtronic Cardiac Rhythm and Heart Failure

People needed

24

Starts

2011-11-01

Expected to finish

2015-02-01

Last updated by the study team

2018-07-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient is 18 years of age or older
• Patient (or patient's legally authorized representative) is willing and able to provide written informed consent
• Patient is willing and able to comply with the protocol, including follow-up visits
• Documented paroxysmal or persistent atrial fibrillation or strong suspicion of atrial fibrillation (i.e, palpitations)
• Patient is indicated for the Reveal XT insertable cardiac monitor or other commercially-available and substantially equivalent Medtronic insertable cardiac monitor
• Recent HF event within prior 120 days (HF event defined as meeting any one of the following two criteria: 1. Admission with primary diagnosis of HF 2. Intravenous HF therapy (e.g. IV diuretics/vasodilators) or ultrafiltration at any one of the following settings: admission with secondary/tertiary diagnosis of HF, emergency department, ambulance, observation unit, urgent care, HF/cardiology clinic, patient's home
• Willing and able to transmit data via CareLink

You may not qualify if…

• Patient is pregnant
• Patient has been participating in another study that may interfere with the IDENTIFY-HF protocol required procedures
• Endstage (Stage D or New York Heart Association class IV) heart failure
• Asymptomatic (Stage B or New York Heart Association class I) heart failure
• Severe aortic stenosis or insufficiency
• Existing insertable cardiac monitor implanted for more than 1 year
• Existing implantable pulse generator, implantable cardioverter defibrillator, cardiac resynchronization therapy device
• Severe renal impairment (estimated glomerular filtration rate <25mL/min)
• Myocardial infarction within prior 30 days

Where it is running

• Scripps Green — La Jolla, California, United States
• Aurora Denver Cardiology Associates — Aurora, Colorado, United States
• Spectrum Health — Grand Rapids, Michigan, United States
• The Valley Hospital — Ridgewood, New Jersey, United States
• Carolinas Medical Center/Sanger Heart & Vascular — Charlotte, North Carolina, United States
• The Ohio State University — Columbus, Ohio, United States
• Lancaster Heart & Stroke Foundation — Lancaster, Pennsylvania, United States
• Medical University of South Carolina — Charleston, South Carolina, United States
• St. Thomas Research Institute — Nashville, Tennessee, United States
• University of Texas Southwestern Medical Center — Dallas, Texas, United States
• Heart Clinic PLLC — McAllen, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.